| 摘要: |
| 目的：为推动中医药治疗腺样体肥大提供参考。方法：检索中国知网、万方、维普数据库，收集2008-2022年以中医药治疗腺样体肥大的文献，筛选文献并提取中药方剂，对方剂的药物频次、四气五味、关联规则进行分析，获取核心药对。通过中医数据库与分析平台（TCMSP）获取核心药对的化学成分及靶点，通过GeneCards、OMIM、DisGeNET数据库获取疾病靶点，基于Cytoscape 3.9.1软件构建中药核心药对-有效活性成分-疾病-靶点网络图并进行拓扑分析。借助Venny平台获取疾病与药物交集靶点，运用STRING数据库、DAVID6.8数据库进行机制分析。结果：筛选得到方剂100首，药物176味，其中使用频次≥15共26味；关联度规则挖掘出辛夷-苍耳子-夏枯草置信度最高。对“辛夷-苍耳子-夏枯草”进行网络药理分析，活性成分主要为槲皮素、木犀草素、山奈酚、豆甾醇和β-谷甾醇，PPI网络分析结果显示关键靶点有IL-6、TNF、AKT1、VEGFA、CASP3等，GO富集分析结果共计925条，KEGG富集通路主要涉及AGE-RAGE信号通路、IL-17信号通路、PI3K-Akt信号通路、TNF信号通路等信号通路。结论：中医药治疗腺样体肥大主要的核心药对为“辛夷-苍耳子-夏枯草”，通过多成分、多靶点、多途径治疗腺样体肥大，其机制可能是调控PI3K-Akt信号通路、IL-17信号通路、TNF信号通路、AGE-RAGE信号通路等生物信号通路来抑制炎症因子的释放，调控细胞增殖和凋亡。 |
| 关键词: 腺样体肥大 数据挖掘 网络药理学 中医药 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2024.02.002 |
|
| 基金项目:北京中医药大学王俊宏教学名师工作坊课题,编号MSGZF-201818。 |
|
| Exploration of Medication Rules and Core Mechanism of Traditional Chinese Medicine in the Treatment of Adenoidal Hypertrophy Based on Data Mining and Network Pharmacology |
| Liu Miaomiao, Yuan Zhenhua, Zhang Qiang, Wang Junhong |
| ((Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100007, China)) |
| Abstract: |
| Objective: To provide reference for promoting the treatment of adenoid hypertrophy with traditional Chinese medicine. Methods: Literature with traditional Chinese medicine in the treatment of adenoid hypertrophy were retrieved from CNKI, Wanfang and VIP databases from 2008 to 2022. Literature were screened and traditional Chinese medicine prescriptions were extracted. The drug frequency, four properties and five flavors and association rules of the prescriptions were analyzed to obtain the core drug pairs. Chemical components and targets of core drug pairs were obtained through traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP), and disease targets were obtained through GeneCards, OMIM and DisGeNET databases. Network diagram of core drug pairs-active components-disease-targets was constructed and topological analysis was performed based on Cytoscape 3.9.1 software. Venny platform was used to obtain the intersection targets of diseases and drugs, STRING and DAVID6.8 databases were used for mechanism analysis. Results: Totally 100 prescriptions and 176 drugs were screened, among which 26 drugs were used ≥15 times. According to the correlation rule, the confidence of “flos magnoliae-fructus xanthii-selfheal” was the highest. The network pharmacological analysis of “flos magnoliae-fructus xanthii-selfheal” was conducted, and the main active components were quercetin, luteolin, kaempferol, stigmasterol and β-sitosterol. Protein-protein interaction (PPI) network analysis results showed that the key targets were interleukin (IL)-6, tumor necrosis factor (TNF), AKT1, vascular endothelial growth factor A (VEGFA), and CASP3. A total of 925 gene ontology (GO) enrichment results were obtained. Kyoto encyclopedia of genes and genomes (KEGG) enrichment pathway mainly included advanced glycosylation end products-receptors of advanced glycosylation end products (AGE-RAGE) signaling pathway, IL-17 signaling pathway, PI3K-Akt signaling pathway, TNF signaling pathway and other signaling pathways. Conclusion: The main core drug pair of traditional Chinese medicine in the treatment of adenoid hypertrophy is “flos magnoliae-fructus xanthii-selfheal”, which is a multi-component, multi-target, multi-pathway treatment for adenoid hypertrophy. Its mechanism may be to regulate PI3K-Akt signaling pathway, IL-17 signaling pathway, TNF signaling pathway, AGE-RAGE signaling pathway and other biological signaling pathways to inhibit the release of inflammatory factors and regulate cell proliferation and apoptosis. |
| Key words: adenoid hypertrophy data mining network pharmacology traditional Chinese medicine |
